Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.57 |
| ▸ | RAB9A | P51151 | 5/20 | 0.57 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.55 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14358480 | 0.90 | MMP13 (0.59) | MAPTALDH1A1KMT2AMEN1RXFP1 | |
| SCHEMBL14358477 | 0.90 | MMP13 (0.59) | MAPTALDH1A1KMT2AMEN1RXFP1 | |
| SCHEMBL18880072 | 0.85 | ALDH1A1 (0.73) | MAPTALDH1A1KMT2AMEN1RXFP1 | |
| SCHEMBL10294626 | 0.82 | ALDH1A1 (0.51) | MAPTALDH1A1KMT2AMEN1RXFP1 | |
| SCHEMBL19592334 | 0.82 | CA1 (0.59) | MAPTALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL21568088 | 0.79 | MAPT (0.71) | MAPTALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL29663991 | 0.79 | RAB9A (0.76) | MAPTALDH1A1KMT2AMEN1RXFP1 | |
| SCHEMBL11402689 | 0.79 | SMN1; SMN2 (0.58) | MAPTALDH1A1KMT2AMEN1RXFP1 | |
| SCHEMBL11720998 | 0.79 | ALDH1A1 (0.47) | MAPTALDH1A1KMT2AMEN1RXFP1 | |
| SCHEMBL10792997 | 0.79 | AAK1 (0.62) | MAPTALDH1A1KMT2ASMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230256098-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2023-08-17 | — | — | US | disclosed |
| US-20230256098-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2023-08-17 | — | — | US | disclosed |
| US-11679158-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11679158-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11633479-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-11612657-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2022-12-15 | — | — | US | disclosed |
| US-20220347302-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2022-11-03 | — | — | US | disclosed |
| US-11382979-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-7598257-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | disclosed |
| US-7550458-B2 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550458-B2 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-20080249081-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN AND SCREENING METHODS THEREFOR | ACADIA PHARMACEUTICALS INC. | 2008-10-09 | — | — | US | disclosed |
| US-7342016-B2 | Farnesyl protein transferase inhibitors as antitumor agents | SCHERING CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| WO-2007070514-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-B]PYRIDINES AND PYRROLO[2,3-B]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | INCYTE CORPORATION | 2007-06-14 | — | — | US | disclosed |
| US-20070088029-A1 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-19 | — | — | US | disclosed |
| US-20070088029-A1 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | MAPT 3547/4885ALDH1A1 3413/4885KMT2A 780/4885 |
| US-11612657-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | MAPT 3534/4885ALDH1A1 3151/4885KMT2A 4005/4885 |
| US-11633479-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | MAPT 3534/4885ALDH1A1 3151/4885KMT2A 4005/4885 |
| US-11382979-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | MAPT 3534/4885ALDH1A1 3151/4885KMT2A 4005/4885 |
| US-20220347302-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | MAPT 3534/4885ALDH1A1 3151/4885KMT2A 4005/4885 |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | JAK1, JAK3, MAP3K4 | MAPT 3688/4885ALDH1A1 2035/4885KMT2A 916/4885 |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | MAPT 3547/4885ALDH1A1 3413/4885KMT2A 780/4885 |
| US-11679158-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | MAPT 3534/4885ALDH1A1 3151/4885KMT2A 4005/4885 |
| US-20230256098-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | MAPT 3534/4885ALDH1A1 3151/4885KMT2A 4005/4885 |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | MAPT 3547/4885ALDH1A1 3413/4885KMT2A 780/4885 |
| US-20080249081-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN AND SCREENING METHODS THEREFOR | MRGPRX2, MRGPRX4, MRGPRX1 | MAPT 3873/4885ALDH1A1 2124/4885KMT2A 3111/4885 |
| US-20070088029-A1 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | VDR, ESRRB, NR5A1 | MAPT 4312/4885ALDH1A1 3634/4885KMT2A 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.